WGS · GeneDx Holdings Corp.
$59.10
-1.08% last session
End-of-day data · updated 2026-07-28
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
54.9
Dividend yield
—
Beta
1.91
Avg volume
1M
Employees
1K
2D change
—
5D change
-4.48%
10D change
-4.63%
30D change
-13.29%
60D change
16.45%
MTD change
-15.58%
YTD change
-53.45%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — WGS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-06-29
Latest call per bank · past 12 months
Wells Fargo
Overweight$75.00
+26.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-29 | Guggenheim | Maintains | Buy | $70.00 → $74.00 |
| 2026-06-23 | Piper Sandler | Maintains | Overweight | $50.00 → $63.00 |
| 2026-05-05 | Canaccord Genuity | Maintains | Buy | $100 → $75.00 |
| 2026-05-05 | Wells Fargo | Maintains | Overweight | $155 → $75.00 |
| 2026-05-05 | Guggenheim | Maintains | Buy | $100 → $70.00 |
| 2026-05-05 | BTIG | Maintains | Buy | $170 → $90.00 |
| 2026-04-20 | Canaccord Genuity | Maintains | Buy | $170 → $100 |
| 2026-03-30 | Guggenheim | Maintains | Buy | $170 → $100 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 46 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 3.1% above the 50-day MA ($58.09).
- Price vs 200-day MA: Trading 35.0% below the 200-day MA ($92.20).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.96) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($34.51) and high ($167.51).
WGS Price Chart
Loading chart for WGS…
Fundamentals
About GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
More in Diagnostics & Research
TMO
Thermo Fisher Scientific Inc
$208B -3.3% YTD
DHR
Danaher Corporation
$138B -13.8% YTD
IDXX
IDEXX Laboratories, Inc.
$44B -17.8% YTD
A
Agilent Technologies, Inc.
$39B 1.9% YTD
NTRA
Natera, Inc.
$37B 12.6% YTD
IQV
IQVIA Holdings, Inc.
$36B -5.4% YTD
WAT
Waters Corporation
$36B -2.3% YTD
ILMN
Illumina, Inc.
$29B 44.5% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.